MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Rigel Pharmaceuticals Market Cap 2011-2026 | RIGL
As of March 03, 2026 Rigel Pharmaceuticals has a market cap of $ 588 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Rigel Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 393 M | 25.9 M | 25.2 M | 436 M | 614 M | 392 M | 348 M | 504 M | 196 M | 243 M | 181 M | 275 M | 479 M | 615 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 615 M | 25.2 M | 338 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
2.77 B | $ 20.36 | -1.64 % | $ 2.57 B | USA |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 0.81 | -3.83 % | $ 4.42 M | China |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
8.67 B | $ 164.62 | -1.06 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 8.57 | -1.95 % | $ 1.39 B | Britain |
 |
Certara
CERT
|
1.08 B | $ 7.27 | 3.05 % | $ 1.17 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
3.04 B | $ 23.94 | 0.23 % | $ 2.93 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
94.1 M | $ 18.1 | 1.17 % | $ 869 M | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Eton Pharmaceuticals
ETON
|
114 M | $ 17.89 | -1.43 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
11.7 B | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
155 M | $ 26.27 | -2.2 % | $ 703 M | USA |
 |
Galapagos NV
GLPG
|
4.42 B | $ 33.2 | -2.61 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
115 M | $ 27.98 | 2.15 % | $ 364 M | USA |
 |
Galecto
GLTO
|
23.4 M | $ 29.63 | -1.39 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
25 B | $ 27.76 | -6.37 % | $ 17.6 B | Danmark |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
291 M | $ 1.0 | -1.47 % | $ 73.4 M | USA |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 69.4 | -0.64 % | $ 8.32 B | USA |
 |
Hoth Therapeutics
HOTH
|
6.57 M | $ 1.01 | -0.98 % | $ 6.44 M | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 28.63 | -0.95 % | $ 1.65 B | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
40.9 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Immuron Limited
IMRN
|
348 M | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
503 M | $ 9.95 | -0.4 % | $ 626 M | Germany |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Immunic
IMUX
|
145 M | $ 1.12 | 5.19 % | $ 174 M | USA |
 |
Agenus
AGEN
|
215 K | $ 3.24 | -3.14 % | $ 1.16 M | USA |
 |
Immunovant
IMVT
|
2.26 B | $ 27.24 | -1.84 % | $ 4.13 B | USA |
 |
Inhibrx
INBX
|
1.75 B | $ 76.35 | -1.47 % | $ 3.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |  Israel |
 |
InMed Pharmaceuticals
INM
|
1.71 M | $ 0.78 | -4.88 % | $ 1.91 M | Canada |
 |
INmune Bio
INMB
|
211 M | $ 1.39 | 4.66 % | $ 25 M | USA |
 |
Insmed Incorporated
INSM
|
31.6 B | $ 147.23 | 0.62 % | $ 29.3 B | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |